245 related articles for article (PubMed ID: 24421886)
41. Bordetella pertussis from functional genomics to intranasal vaccination.
Locht C; Antoine R; Raze D; Mielcarek N; Hot D; Lemoine Y; Mascart F
Int J Med Microbiol; 2004 Apr; 293(7-8):583-8. PubMed ID: 15149035
[TBL] [Abstract][Full Text] [Related]
42. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis.
Feunou PF; Bertout J; Locht C
PLoS One; 2010 Apr; 5(4):e10178. PubMed ID: 20419113
[TBL] [Abstract][Full Text] [Related]
43. Mucosal Immunization Against Pertussis: Lessons From the Past and Perspectives.
Dubois V; Locht C
Front Immunol; 2021; 12():701285. PubMed ID: 34211481
[TBL] [Abstract][Full Text] [Related]
44. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
[TBL] [Abstract][Full Text] [Related]
45. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
[TBL] [Abstract][Full Text] [Related]
46. Intranasal Immunization with Acellular Pertussis Vaccines Results in Long-Term Immunity to Bordetella pertussis in Mice.
Wolf MA; Boehm DT; DeJong MA; Wong TY; Sen-Kilic E; Hall JM; Blackwood CB; Weaver KL; Kelly CO; Kisamore CA; Bitzer GJ; Bevere JR; Barbier M; Damron FH
Infect Immun; 2021 Feb; 89(3):. PubMed ID: 33318136
[No Abstract] [Full Text] [Related]
47. Controlled Human Infection With Bordetella pertussis Induces Asymptomatic, Immunizing Colonization.
de Graaf H; Ibrahim M; Hill AR; Gbesemete D; Vaughan AT; Gorringe A; Preston A; Buisman AM; Faust SN; Kester KE; Berbers GAM; Diavatopoulos DA; Read RC
Clin Infect Dis; 2020 Jul; 71(2):403-411. PubMed ID: 31562530
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
Wood N; Nolan T; Marshall H; Richmond P; Gibbs E; Perrett K; McIntyre P
JAMA Pediatr; 2018 Nov; 172(11):1045-1052. PubMed ID: 30208475
[TBL] [Abstract][Full Text] [Related]
49. Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
Taranger J; Trollfors B; Bergfors E; Knutsson N; Lagergård T; Schneerson R; Robbins JB
Pediatrics; 2001 Dec; 108(6):E115. PubMed ID: 11731642
[TBL] [Abstract][Full Text] [Related]
50. Investigating
de Graaf H; Gbesemete D; Gorringe AR; Diavatopoulos DA; Kester KE; Faust SN; Read RC
BMJ Open; 2017 Oct; 7(10):e018594. PubMed ID: 29025851
[TBL] [Abstract][Full Text] [Related]
51. Efficacy of an acellular pertussis vaccine among adolescents and adults.
Ward JI; Cherry JD; Chang SJ; Partridge S; Lee H; Treanor J; Greenberg DP; Keitel W; Barenkamp S; Bernstein DI; Edelman R; Edwards K;
N Engl J Med; 2005 Oct; 353(15):1555-63. PubMed ID: 16221778
[TBL] [Abstract][Full Text] [Related]
52. A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Leroux-Roels G; Lattanzi M; Solis CD; Contorni M; Costantini M; Moraschini L; Bardelli M; Bertholet S; Borgogni E; Buricchi F; Cantisani R; Faenzi E; Finco O; Leuzzi R; Pizza M; Rosa D; Schiavetti F; Seubert A; Spensieri F; Volpini G; Zedda L; Giudice GD; Galgani I
Hum Vaccin Immunother; 2018 Jan; 14(1):45-58. PubMed ID: 29172945
[TBL] [Abstract][Full Text] [Related]
53. Serum reactome induced by Bordetella pertussis infection and Pertussis vaccines: qualitative differences in serum antibody recognition patterns revealed by peptide microarray analysis.
Valentini D; Ferrara G; Advani R; Hallander HO; Maeurer MJ
BMC Immunol; 2015 Jul; 16():40. PubMed ID: 26129684
[TBL] [Abstract][Full Text] [Related]
54. New Pertussis Vaccines: A Need and a Challenge.
Hozbor D
Adv Exp Med Biol; 2019; 1183():115-126. PubMed ID: 31432399
[TBL] [Abstract][Full Text] [Related]
55. Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine.
Dalby T; Petersen JW; Harboe ZB; Krogfelt KA
J Med Microbiol; 2010 Sep; 59(Pt 9):1029-1036. PubMed ID: 20508003
[TBL] [Abstract][Full Text] [Related]
56. Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e.
Kammoun H; Roux X; Raze D; Debrie AS; De Filette M; Ysenbaert T; Mielcarek N; Saelens X; Fiers W; Locht C
PLoS One; 2013; 8(3):e59198. PubMed ID: 23555631
[TBL] [Abstract][Full Text] [Related]
57. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
Giuliano M; Mastrantonio P; Giammanco A; Piscitelli A; Salmaso S; Wassilak SG
J Pediatr; 1998 Jun; 132(6):983-8. PubMed ID: 9627590
[TBL] [Abstract][Full Text] [Related]
58. Placebo-controlled trial of two acellular pertussis vaccines in Sweden--protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines.
Lancet; 1988 Apr; 1(8592):955-60. PubMed ID: 2896826
[TBL] [Abstract][Full Text] [Related]
59. Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model.
Kwon HJ; Han SB; Kim BR; Kang KR; Huh DH; Choi GS; Ahn DH; Kang JH
BMC Infect Dis; 2017 Apr; 17(1):247. PubMed ID: 28376777
[TBL] [Abstract][Full Text] [Related]
60. Clinical testing of pre-pandemic live attenuated A/H5N2 influenza candidate vaccine in adult volunteers: results from a placebo-controlled, randomized double-blind phase I study.
Rudenko L; Kiseleva I; Stukova M; Erofeeva M; Naykhin A; Donina S; Larionova N; Pisareva M; Krivitskaya V; Flores J;
Vaccine; 2015 Sep; 33(39):5110-7. PubMed ID: 26296497
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
